LENEXA, K.S., Dec. 13, 2005 (PRIMEZONE) -- Mediware Information Systems, Inc. (Nasdaq:MEDW) announces today that NYU Medical Center, one of the nation's most progressive teaching hospitals, continues to lead through innovation and modernization of the healthcare process by selecting Mediware's HCLL(tm) Transfusion and HCLL(tm) Donor solutions to sustain the delivery of high-quality care in a safe environment.
NYU Medical Center is committed to patient safety initiatives and fostering a culture of best practices for the delivery of care throughout the institution. "Our focus was a system designed with sound blood bank principles and intelligent presentation of the data elements to our end users. Mediware enables the technologist or supervisor to have immediate access to patient data including transfusion history, current testing readiness, special blood attribute requirements, contents of inventory and donor history," said Mark Wheeler, Blood Bank Administrative Director.
The Blood Bank has been deemed mission critical at NYU Medical Center and an integral component of the larger institutional commitment to be a technology leader. The Medical Center has recognized Mediware and their twenty-year relationship as the cornerstone of the principal safety control system of the Blood Bank, protecting patients, physicians and blood bankers from error.
"We wanted to leverage our investment in the historical donor and patient data bases, maintain the highest standards of the donor and patient safety inventory control functions, and align ourselves with a partner who would support us well into the future," Wheeler noted.
"The vision for patient safety that NYU Medical Center demonstrates is a model for all large-scale health systems. Mediware's commitment to patient safety shares this mission to eliminate error and variance from the care process. We are proud of our long-standing partnership with the Medical Center as they raise the standards and best practices for the delivery of healthcare," said James Burgess, President and CEO, Mediware Information Systems.
About NYU Medical Center
One of the world's premier academic medical institutions for more than 155 years, NYU Medical Center continues to be a leader in patient care, physician education and scientific research. NYU Medical Center is internationally renowned for excellence in areas such as cardiovascular disease, pediatrics, skin care, neurosurgery, urology, cancer care, rehabilitation, plastic surgery, minimally invasive surgery, transplant surgery, infertility, women's health, and day surgery.
About Mediware
Mediware is a leading provider of software solutions and services for medication management, blood and other cellular products and perioperative departments. With over 1,100 worldwide installations, Mediware provides hospitals, clinics, correctional institutions, blood centers and other, public and private, health care institutions with proprietary software solutions for blood donor testing and distribution, transfusion services, tissue management, cord blood processing and stem cell management, pharmacy, medication management, ordering and electronic prescribing, and operating room scheduling, preference management, and documentation. Mediware provides a full suite of support and related services for each of its solutions. For more information about Mediware, its services and products, including HCLL(tm) Transfusion and Donor and LifeTrak(r), WORx(r), MediMAR(r), MediCOE(tm), Perioperative Solutions(tm), and JAC medicine management systems, visit www.Mediware.com.
Certain statements in this press release may constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the "Act") and in releases made by the SEC from time to time. Such forward-looking statements are not based on historical facts and involve known and unknown risks, uncertainties and other factors disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2005, which may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward-looking statements. The Company disclaims any obligation to update its forward-looking statements.